TScan Therapeutics (NASDAQ:TCRX) Rating Increased to Hold at Wall Street Zen

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Other research analysts have also issued reports about the stock. HC Wainwright decreased their price target on shares of TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Wedbush reiterated an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Morgan Stanley reissued an "overweight" rating and set a $10.00 price objective on shares of TScan Therapeutics in a research report on Friday, March 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $9.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, April 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $7.80.

TScan Therapeutics Trading Down 1.6%

NASDAQ:TCRX opened at $1.81 on Friday. The company has a fifty day moving average of $1.50 and a 200 day moving average of $1.83. TScan Therapeutics has a 52 week low of $1.02 and a 52 week high of $7.89. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $102.43 million, a P/E ratio of -1.66 and a beta of 0.97.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.62 million. On average, research analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Insider Activity

In related news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of TScan Therapeutics stock in a transaction dated Tuesday, May 20th. The shares were purchased at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the transaction, the insider directly owned 7,946,141 shares in the company, valued at approximately $9,535,369.20. This represents a 17.79% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after purchasing an additional 5,694 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of TScan Therapeutics by 5.2% in the fourth quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Woodline Partners LP raised its holdings in shares of TScan Therapeutics by 6.7% in the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company's stock valued at $352,000 after acquiring an additional 7,282 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of TScan Therapeutics by 0.9% in the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock valued at $1,230,000 after acquiring an additional 7,744 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of TScan Therapeutics by 16.3% in the fourth quarter. Barclays PLC now owns 67,508 shares of the company's stock valued at $206,000 after acquiring an additional 9,441 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.